Genta Plans Confirmatory Trial To Extend Genasense To First Line CLL Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genta hopes to use a confirmatory trial for Genasense to expand the patient population of the lymphocytic leukemia agent to treatment-naïve patients